BioVaria Startup Pitch & Partner Awards go to Exactmer and Lymphatica Medtech

  

 

16 May 2022, Munich – This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting academia–industry partnering. Following two years of mainly virtual interaction, the event was well received by investors and decision makers from industry as well as academic inventors, entrepreneurs and their technology transfer partners.
Over 60 licensable innovations were presented by leading academics and clinicians from all over Europe, from therapeutic and diagnostic approaches to platform technologies.


BioVaria’s interactive panel showcased 13 hand-picked start-ups, competing against each other for the StartUp Pitch & Partner Award. The winners, chosen by a jury of leading investors, are Exactmer in the category ‘Emerging’ and ‘Lymphatica Medtech’ in the category ‘Rising’. Exactmer, a spin-out from Imperial College, London, UK, pursues a completely new approach to the synthesis of bio- and synthetic polymers for use in new medicines. Their proprietary technology allows the production of supremely accurate polymers at drastically reduced cost. Lymphatica Medtech is a Swiss company developing medical devices for the treatment of lymphatic diseases. Its lead product LymphoDRAIN™, the first active implantable lymphatic shunt for the treatment of chronic lymphedema, has started clinical trials at the end of last year. If successful, it could increase the quality of life of millions of people suffering from lymphatic disease who have currently no therapeutic options other than life-long manual drainage and compression therapy.


‘I'm very honoured to have received the award among a cohort of impressive companies. Apart from this recognition, being able to participate in this outstanding event and foster communication with relevant investors face to face, are key elements for our company growth,’ said Marco Pisano, Co-Founder and CEO of Lymphatica Medtech.

‘Exactmer are delighted to have received the BioVaria Start Up Pitch and Partner Award. It was wonderful to meet such strong talents and innovators. It has been a truly inspiring event and we would like to thank the organisers for making it possible,‘ stated Dara O'Brien, Development and Operations Associate at Exactmer.


Another highlight of this year’s BioVaria was a special lecture by European Patent Office experts providing insights on patenting antibodies and vaccines.


Ascenion, who organized the event in collaboration with 14 European technology transfer organizations, is grateful to all partners, sponsors, speakers, moderators and participants who ensured the success and contributed to the vibrant spirit of this year’s BioVaria. ‘It’s almost like coming home,’ one of the sponsors said, reflecting the view of many participants who value the event not only for the outstanding quality of technologies and start-ups, but also for its trusting, almost familiar atmosphere.


The next BioVaria will be held on 24-25 April 2023 in Munich.


Summaries of all the technologies and start-ups presented are available on the BioVaria website. Registered participants can still arrange follow-on meetings using the BioVaria virtual platform.

 

###

 

Patron:
Bavarian Ministry of Economic Affairs, Regional Development and Energy

Sponsors:
BioM, Abbvie, Else Kröner-Fresenius-Stiftung/ForTra gGmbH, Galapagos Biopharma Germany GmbH, Johnson & Johnson Innovation, MSD, Gimv, HERTIN & Partner, Kador & Partner, NLC, Vossius, Withers & Rogers

Startup-Sponsors:
BaseLaunch, EQT Life Sciences, IRBM

Technology transfer partners:
Ascenion, BayPAT, DZIF – German Center for Infection Research, EMBLEM Technology Transfer, Innovectis, IOCB Tech, Lead Discovery Center, LMU Munich, Max Planck Innovation, Netval, Oxford University Innovation, PROvendis, TransferAllianz, University Hospital Hradec Králové, VIS

Network partners:
ASTP, BIO Deutschland, BioRN, LISAvienna

Communication sponsors:
Eurasanté, Going Public, transkript

 

About BioVaria

BioVaria brings together leading tech transfer professionals, innovators from academia and startups with investors and representatives of the global biotech and pharma industry.

Key features of BioVaria:

  • Unique gathering of Europe's top scientists, entrepreneurs, technology transfer professionals, investors and industry representatives
  • Presentation of more than 70 licensable technologies and startups originating from public research institutions and universities across Europe
  • Focus on patent-protected, commercially attractive opportunities covering therapeutics, diagnostics and research tools in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas
  • Startup Pitch & Partner program with a competition for the BioVaria Startup Award, one-on-one mentoring and startup-investor speed dating
  • Ample space to discuss scientific details face-to-face with the inventors and entrepreneurs
  • Jointly organized by Ascenion and a selected group of leading European technology transfer organizations


Further information and technologies: www.biovaria.org

 

About Ascenion

Ascenion is an independent technology transfer company focussing on the life sciences. It is partner to over 30 research organizations, universities and university hospitals in Germany and Europe, including life-science institutes of the Helmholtz and Leibniz Associations, the Charité, the Hannover Medical School, the Medical University of Innsbruck and the University Medical Center Göttingen. Ascenion’s multidisciplinary, industry-experienced team works closely with its partners to tap the potential of their research by identifying promising results, obtaining patent protection, and turning pure science into applied technology. Particular strengths are spin-off support and project development, where early-stage projects are transformed into assets that attract potential investors and licensees. This has led to the founding of numerous new companies and the transfer of innovative medical approaches into approved drugs, changing the lives of thousands of patients. Profits from Ascenion’s operative business and exit proceeds flow via its parent company, the LifeScience Foundation for the Promotion of Science and Research, to fund further translational research at its partner institutes.


Further information at: www.ascenion.de

 

###
 

Contact

Stanislava Zollner, Corporate Communication, Ascenion GmbH
zollner(at)ascenion(dot)de, +49 89 3188140

 

News

BioVaria Startup Pitch & Partner Awards go to Exactmer and Lymphatica Medtech

  

 

16 May 2022, Munich – This year’s hybrid BioVaria brought together over 230 life-science innovators – most of them live in Munich – boosting academia–industry partnering. Following two years of mainly virtual interaction, the event was well received by investors and decision makers from industry as well as academic inventors, entrepreneurs and their technology transfer partners.
Over 60 licensable innovations were presented by leading academics and clinicians from all over Europe, from therapeutic and diagnostic approaches to platform technologies.


BioVaria’s interactive panel showcased 13 hand-picked start-ups, competing against each other for the StartUp Pitch & Partner Award. The winners, chosen by a jury of leading investors, are Exactmer in the category ‘Emerging’ and ‘Lymphatica Medtech’ in the category ‘Rising’. Exactmer, a spin-out from Imperial College, London, UK, pursues a completely new approach to the synthesis of bio- and synthetic polymers for use in new medicines. Their proprietary technology allows the production of supremely accurate polymers at drastically reduced cost. Lymphatica Medtech is a Swiss company developing medical devices for the treatment of lymphatic diseases. Its lead product LymphoDRAIN™, the first active implantable lymphatic shunt for the treatment of chronic lymphedema, has started clinical trials at the end of last year. If successful, it could increase the quality of life of millions of people suffering from lymphatic disease who have currently no therapeutic options other than life-long manual drainage and compression therapy.


‘I'm very honoured to have received the award among a cohort of impressive companies. Apart from this recognition, being able to participate in this outstanding event and foster communication with relevant investors face to face, are key elements for our company growth,’ said Marco Pisano, Co-Founder and CEO of Lymphatica Medtech.

‘Exactmer are delighted to have received the BioVaria Start Up Pitch and Partner Award. It was wonderful to meet such strong talents and innovators. It has been a truly inspiring event and we would like to thank the organisers for making it possible,‘ stated Dara O'Brien, Development and Operations Associate at Exactmer.


Another highlight of this year’s BioVaria was a special lecture by European Patent Office experts providing insights on patenting antibodies and vaccines.


Ascenion, who organized the event in collaboration with 14 European technology transfer organizations, is grateful to all partners, sponsors, speakers, moderators and participants who ensured the success and contributed to the vibrant spirit of this year’s BioVaria. ‘It’s almost like coming home,’ one of the sponsors said, reflecting the view of many participants who value the event not only for the outstanding quality of technologies and start-ups, but also for its trusting, almost familiar atmosphere.


The next BioVaria will be held on 24-25 April 2023 in Munich.


Summaries of all the technologies and start-ups presented are available on the BioVaria website. Registered participants can still arrange follow-on meetings using the BioVaria virtual platform.

 

###

 

Patron:
Bavarian Ministry of Economic Affairs, Regional Development and Energy

Sponsors:
BioM, Abbvie, Else Kröner-Fresenius-Stiftung/ForTra gGmbH, Galapagos Biopharma Germany GmbH, Johnson & Johnson Innovation, MSD, Gimv, HERTIN & Partner, Kador & Partner, NLC, Vossius, Withers & Rogers

Startup-Sponsors:
BaseLaunch, EQT Life Sciences, IRBM

Technology transfer partners:
Ascenion, BayPAT, DZIF – German Center for Infection Research, EMBLEM Technology Transfer, Innovectis, IOCB Tech, Lead Discovery Center, LMU Munich, Max Planck Innovation, Netval, Oxford University Innovation, PROvendis, TransferAllianz, University Hospital Hradec Králové, VIS

Network partners:
ASTP, BIO Deutschland, BioRN, LISAvienna

Communication sponsors:
Eurasanté, Going Public, transkript

 

About BioVaria

BioVaria brings together leading tech transfer professionals, innovators from academia and startups with investors and representatives of the global biotech and pharma industry.

Key features of BioVaria:

  • Unique gathering of Europe's top scientists, entrepreneurs, technology transfer professionals, investors and industry representatives
  • Presentation of more than 70 licensable technologies and startups originating from public research institutions and universities across Europe
  • Focus on patent-protected, commercially attractive opportunities covering therapeutics, diagnostics and research tools in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas
  • Startup Pitch & Partner program with a competition for the BioVaria Startup Award, one-on-one mentoring and startup-investor speed dating
  • Ample space to discuss scientific details face-to-face with the inventors and entrepreneurs
  • Jointly organized by Ascenion and a selected group of leading European technology transfer organizations


Further information and technologies: www.biovaria.org

 

About Ascenion

Ascenion is an independent technology transfer company focussing on the life sciences. It is partner to over 30 research organizations, universities and university hospitals in Germany and Europe, including life-science institutes of the Helmholtz and Leibniz Associations, the Charité, the Hannover Medical School, the Medical University of Innsbruck and the University Medical Center Göttingen. Ascenion’s multidisciplinary, industry-experienced team works closely with its partners to tap the potential of their research by identifying promising results, obtaining patent protection, and turning pure science into applied technology. Particular strengths are spin-off support and project development, where early-stage projects are transformed into assets that attract potential investors and licensees. This has led to the founding of numerous new companies and the transfer of innovative medical approaches into approved drugs, changing the lives of thousands of patients. Profits from Ascenion’s operative business and exit proceeds flow via its parent company, the LifeScience Foundation for the Promotion of Science and Research, to fund further translational research at its partner institutes.


Further information at: www.ascenion.de

 

###
 

Contact

Stanislava Zollner, Corporate Communication, Ascenion GmbH
zollner(at)ascenion(dot)de, +49 89 3188140